跳至主要内容
临床试验/IRCT20190914044769N1
IRCT20190914044769N1招募中3 期

The efficacy of pentoxifylline adjunctive therapy on cognitive deficits and symptoms of patients with schizophrenia: A randomized placebo-controlled clinical trial

Mashhad University of Medical Sciences0 个研究点目标入组 52 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
52

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 55 years(—)
性别
All

入选标准

  • Diagnosis of schizophrenia based on DSM-5 criteria
  • Patients aged 18-55 years
  • Completion of the consent form by the patient or his / her family
  • Education level at least eighth grade
  • Absence of other concurrent psychiatric disorders
  • Absence of liver and kidney disorders
  • Absence of medical illness leads to psychiatric symptoms
  • No substance use except for smoking
  • Absence of serious cognitive impairment
  • Absence of risk factor for bleeding
  • Patients who are prescribed antipsychotics for risperidone, olanzapine or aripiperazole.
  • Onset of illness under 45 years

排除标准

  • Hypersensitivity reaction or any unbearable side effect caused by the drug
  • Unwillingness to continue taking the drug and continue the project

研究者

相似试验